Exhibit 99.1
Patents Owned or Licensed by MedImmune, Inc.
Product/ Project | US Patent No. | Subject Matter | Expiration Date | |||
---|---|---|---|---|---|---|
E. coli | ||||||
4,795,803 | Adhesin antigens | 1/3/2006 | ||||
5,804,198 | Adhesin vaccines | 9/8/2015 | ||||
6,291,649 | Anti-adhesin antibodies | 3/2/2005 | ||||
6,500,434 | Chaperone and Adhesin Proteins: Vaccines, Diagnostic and Methods for Treating Infections | 4/23/2019 | ||||
Vitaxin | ||||||
5,753,230 | Use of antibodies anti-avb3 antibodies to inhibit angiogenesis in tumors and inflamed tissue | 5/19/2015 | ||||
6,590,079 | Anti-avb3 recombinant human antibodies, nucleic acids encoding same | 1/30/2017 | ||||
6,531,580 | Anti-avb3 recombinant human antibodies, nucleic acids encoding same | 6/24/2019 | ||||
6,596,850 | Anti-avb3 recombinant human antibodies, nucleic acids encoding same | 1/30/2018 | ||||
MEDI-507 | ||||||
5,730,979 | Anti-CD2 antibodies and their use in treating T-cell mediated immune responses | 3/24/2015 | ||||
5,951,983 | Anti-CD2 antibodies and their use in treating T-cell mediated immune responses | 9/14/2016 | ||||
5,817,311 | Use of anti-CD2 antibodies in treating T-cell mediated immune responses | 10/6/2015 | ||||
HPV | ||||||
6,228,368 | Capsomeres containing HPV L1 protein and their use in preventing and treating HPV infection | 10/6/2017 | ||||
6,066,324 | HPV VLPs containing L1 protein with deletions | 10/9/2015 | ||||
6,261,765 | Disassembly/reassembly of Papillomavirus Virus Like Particles | 9/5/2017 | ||||
6,165,471 | HPV capsomeres with reduced assembly capacity | 7/2/2018 | ||||
6,153,201 | Oral Immunization with Papillomavirus Virus Like Particles | 3/9/2013 | ||||
6,361,778 | Papillomavirus Like Particles, Fusion Proteins as well as Processes for Their Production | 9/16/2019 | ||||
6,416,945 | Disassembly/reassembly of Papillomavirus Virus Like Particles | 9/5/2017 | ||||
6,599,508 | Papillomavirus like particles, Fusion Proteins, as well as Processes for their Production | 10/09/2015 | ||||
RSV | ||||||
6,656,467 | Ultra high affinity neutralizing antibodies | 1/26/2021 | ||||
5,824,307 | Synagis® & other anti-RSV antibodies and their use in treating or preventing RSV infection | 10/20/2015 | ||||
5,582,827 | Immunoglobulin from plasma for treatment of RSV | 12/10/2013 | ||||
4,800,078 | Treatment of respiratory disease caused by RSV using human gamma globulin | 1/24/2006 | ||||
5,412,077 | Effective Antibody Titers Against Respiratory Viruses | 8/4/2020 | ||||
6,565,849 | Methods of Enhancing Activity of Vaccines and Vaccine Compositions | 3/02/2021 | ||||
Strep | ||||||
5,928,900 | Pad1 protein | 7/27/2016 | ||||
5,981,229 | DNA encoding Exp1 and PlpA proteins | 11/9/2016 | ||||
5,834,278 | DNA encoding pneumococcal MsrA | 5/1/2016 | ||||
6,245,335 | Streptococcal choline binding proteins | 5/1/2017 | ||||
5,736,367 | Vectors and Prokaryotes which Autocatalytically Delete Resistance | 4/7/2018 | ||||
5,798,243 | Bacterial Peptide Methionine Sulfoxide Reductase an Adhesion Associated Protein, and Antibiotic Therapies | 5/1/2016 | ||||
6,420,135 | Streptococcus pneumoniae polynucleotides and sequences | 10/03/17 | ||||
6,503,511 | Derivatives of Choline Binding Proteins for Vaccines | 4/6/2019 | ||||
6,582,706 | Streptococcus Pneumoniae Protein and Immunogenic Fragments for Vaccine | 12/21/2019 | ||||
IL-9 | ||||||
5,157,112 | Antibodies which specifically bind mammalian T cell growth factor P40 | 10/20/2009 | ||||
6,037,149 | DNA and RNA molecules that encode Met-IL-9 and their use for recombinant production | 8/23/2016 | ||||
5,580,753 | DNA molecules encoding IL-9 and their use for recombinant production | 12/3/2013 | ||||
�� | 5,734,037 | Nucleic acid molecules that hybridize to DNA encoding IL-9 | 5/23/2009 | |||
5,414,071 | Human IL-9 protein | 5/9/2012 | ||||
5,164,317 | Method for enhancing proliferation of mast cells using IL-9 | 3/23/2010 | ||||
5,132,109 | Method for enhancing IgG production using IL-9 and IL-4 | 10/5/2010 | ||||
5,246,701 | Method to inhibit IgE production using anti-IL-9 antibodies or other IL-9 inhibitors | 10/5/2010 | ||||
5,962,269 | Processes and hybridomas for producing anti-IL-9 receptor antibodies | 10/5/2016 | ||||
6,261,559 | Treating asthmatic symptoms using anti-IL-9 antibodies | 8/23/2016 | ||||
5,789,237 | Nucleic acid molecules that hybridize to DNAs encoding human and murine IL-9 receptors | 8/4/2015 | ||||
5,750,377 | Methods for production of mammalian T cell growth factor P40 | 5/12/2015 | ||||
5,116,951 | IL-9 receptor protein | 9/19/2010 | ||||
5,587,302 | Nucleic acid molecules encoding mammalian T cell growth factor P40 | 12/24/2013 | ||||
5,208,218 | Mammalian T cell growth factor P40 protein | 5/4/2010 | ||||
5,180,678 | Methods of detecting IL-9 | 9/19/2010 | ||||
6,602,850 | Method of treating asthma using soluble IL-9 receptor variants | 8/23/2016 | ||||
Ethyol | ||||||
5,424,471 | Process for preparing crystalline forms | 7/13/2012 | ||||
5,591,731 | Dosage forms of crystalline amifostine | 7/31/2012 | ||||
5,824,664 | Agents and methods for inhibiting HIV viral and protein expression using compounds that belong to a family which contains amifostine | 10/20/2015 | ||||
5,846,958 | Methods of stimulating hematopoietic progenitor cells using a compound that belong to a family which contains amifostine | 12/8/2015 | ||||
5,906,984 | Methods of stimulating hematopoietic progenitor cells using specific compounds, which include amifostine | 2/17/2015 | ||||
5,994,409 | Methods of treating toxicities associated with chemotherapy, a method of treating a nephrodisorder, and a method of treating xerostomia, all of which use a compound that belongs to a family which contains amifostine | 12/9/2017 | ||||
6,051,563 | Subcutaneous administration, method of protecting against toxicities associated with ionizing radiation | 2/12/2017 | ||||
6,127,351 | Methods of treating or protecting against toxicities associated with chemotherapy using a specific dosing regime, a method of stimulating bone marrow growth, and a method of treating myelodysplastic syndrome, all of which use a compound that belongs to a family which contains amifostine | 2/12/2017 | ||||
6,218,377 | Methods of treating or protecting against toxicities associated with specific chemotherapy agents, and a method of protecting normal tissue in cancer patients, both of which use a compound that belongs to a family which contains amifostine | 2/12/2017 | ||||
6,239,119 | Methods of treating damaged or infected mucosal tissue using a compounds that belongs to a family which contains amifostine | 4/26/2019 | ||||
6,384,259 | Stable Amorphous Amifostine Composition and Methods for the Preparation and Use of the Same | 11/16/2018 | ||||
6,407,278 | Stable Amorphous Amifostine Composition and Methods for the Preparation and Use of the Same | 11/16/2018 | ||||
6,489,312 | Novel Pharmaceutical Formulations Comprising Aminoalkyl Phosphorothioates | 6/15/2019 | ||||
6,586,476 | Methods for Treatment of Neuro and Nephro Disorders and Therapeutic Toxicities Using Aminothiol Compounds | 12/09/2017 | ||||
6,573,253 | Methods of the Administration of Amifostine and Related Compounds | 2/12/2017 | ||||
NeuTrexin | ||||||
5,716,960 | Cystalline glucuronate hydrate salt | 2/10/2015 | ||||
6,017,921 | Crystalline glucuronate salt | 1/13/2015 | ||||
6,017,922 | Thermally stable crystalline non-salts | 5/18/2018 | ||||
6,258,821 | Trimetrexate ascorbate and compositions comprising trimetrexate and ascorbic acid | 4/26/2019 | ||||
6,258,952 | Methods of producing monohydrate | 5/18/2018 | ||||
4,376,858 | 2,4-Diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline salts | 10/31/2004 | ||||
4,694,007 | Use of Trimetrexate as Antiparasitic Agent | 9/15/2006 | ||||
4,677,219 | Substituted Benzonitriles | 7/17/2006 | ||||
5,160,727 | Tumor Cell Sensitization Method | 3/21/2010 | ||||
6,576,635 | Novel Compositions Comprising Trimetrexate | 10/26/2019 | ||||
PALA | ||||||
5,491,135 | Methods of treating a viral infections (e.g., hepatitis B and C and secondary to HIV 1) | 2/13/2013 | ||||
Platinum | ||||||
4,895,935 | Platinum Pharmaceuticals | 1/23/2007 | ||||
CMV | ||||||
6,291,236 | Human CMV sequences and attenuated viruses | 3/31/2015 | ||||
5,925,751 | Human CMV sequences and attenuated viruses | 3/31/2015 | ||||
5,721,354 | Human CMV sequences and attenuated viruses | 3/31/2015 | ||||
6,040,170 | Human CMV sequences and attenuated viruses | 3/31/2015 | ||||
6,635,477 | Human CMV sequences and attenuated viruses | 3/31/2015 | ||||
EBV | ||||||
4,707,358 | Epstein-Barr virus gp350 subunit protein vaccine | 11/17/2004 | ||||
6,054,130 | Non-splicing variants of EBV gp350 protein and gene | 4/18/2014 | ||||
5,824,508 | Non-splicing variants of EBV gp350 protein and gene | 4/18/2014 | ||||
6,458,364 | Non-Splicing Variants of GP350/220 | 04/24/2020 | ||||
Influenza | ||||||
5,690,937 | Temperature sensitive mutants of influenza | 6/5/2015 | ||||
6,090,391 | Recombinant tryptophan mutants of influenza PB2 gene | 2/23/2016 | ||||
6,322,967 | Recombinant tryptophan mutants of influenza PB2 gene | 2/23/2016 | ||||
6,528,064 | Recombinant tryptophan mutants of influenza | 2/23/2016 | ||||
HSV | ||||||
4,554,159 | Vaccine against HSV-1 and HSV-2 | 11/19/2002 | ||||
4,769,331 | Recombinant herpes simplex cloning methods and materials | 9/6/2005 | ||||
4,859,587 | Recombinant herpes simplex vectors and vaccines | 8/22/2006 | ||||
5,288,641 | Herpes simplex as a vector | 2/22/2011 | ||||
5,328,688 | Recombinant herpes simplex with 34.5 gene knockout | 6/12/2011 | ||||
5,599,691 | Herpes simplex as a vector | 2/4/2014 | ||||
5,641,651 | Synthetic HSV promoters and uses | 6/24/2014 | ||||
5,714,153 | Recombinant herpes simplex vaccines and vectors | 12/23/2012 | ||||
5,846,707 | Herpes simplex as a vector | 6/4/2004 | ||||
5,922,328 | Gamma 34.5 mutants of herpes simplex viruses | 9/11/2016 | ||||
6,071,692 | Herpes simplex as a gene expression vector and vaccine | 6/4/2004 | ||||
6,120,773 | Gamma 34.5 gene modification of herpes simplex viruses | 9/19/2017 | ||||
Negative Stranded RNA Viruses | ||||||
5,166,057 | Recombinant negative strand RNA viruses | 11/24/2009 | ||||
5,578,473 | Recombinant negative strand RNA viruses | 11/24/2009 | ||||
5,786,199 | Recombinant negative strand RNA viruses and vaccines | 7/28/2015 | ||||
5,820,871 | Recombinant negative strand RNA viruses—bicistronic | 10/13/2015 | ||||
5,854,037 | Recombinant negative strand RNA viruses | 12/29/2015 | ||||
6,001,634 | Recombinant negative strand RNA viruses | 8/28/2009 | ||||
6,022,726 | Attenuated negative strand RNA viruses and methods | 2/8/2017 | ||||
6,316,243 | Recombinant attenuated double strand RNA viruses | 11/13/2018 | ||||
5,840,520 | Recombinant RSV viruses | 11/24/2015 | ||||
VZV | ||||||
6,087,170 | VZV gene and mutant VZV viruses | 4/28/2014 |